Header Forschung

Department of Radiation Oncology

The focus of activities at the OncoRay – National Center for Radiation Research in Oncology is translational research, which means that lab results should reach the patient as quickly as possible. OncoRay researchers thus get together with physicians from the Department of Radiotherapy and Radiooncology at Dresden University Hospital to conduct clinical studies examining promising research results. Furthermore, clinician scientists who work as physicians and researchers build a natural bridge between clinic and lab. Often, other hospitals, research groups and industrial partners are also involved on both a national and international level.

The OncoRay Center is an umbrella research platform, assembling 80 researchers from the three operating institutions: the University Hospital Carl Gustav Carus Dresden, the Carl Gustav Carus Faculty of Medicine at TU Dresden and the Helmholtz-Zentrum Dresden-Rossendorf. At OncoRay, they work in cross-disciplinary programs with focuses on medicine, physics, biology and information science.

Main fields of research are (selection):

  • Biologically individualized radiotherapy including preclinical biomarker development
  • Modeling of treatment effects for individualized patient selection for particle therapy and different beam qualities
  • Image-guided radiotherapy
  • Technological optimization of proton therapy including laser-accelerated particle radiotherapy
  • Combined treatments, e.g. with targeted therapies, preclinical and clinical

First patient treatment with proton therapy using interfractional proton range verification by Prompt Gamma-Ray Imaging (PGI). The photograph shows the patient, the proton beam exit (nozzle, right), and the prototype Knife-Edge Slit Camera by IBA, positioned behind the patient's head perpendicular to the beam direction. It was taken just after checking the patient's and the camera's positions.(http://www.sciencedirect.com/science/article/pii/S0167814016000074)


Left: Survival of tumor cells in 3D matrix after combined treatment with radiation and molecular drugs.
Right: immunofluorescence of integrins in tumor cells; transcriptome and proteome analyses in tumor cells after treatment.

Seidlitz A, Beuthien-Baumann B, Löck S, Jentsch C, Platzek I, Zöphel K, Linge A, Kotzerke J, Petr J, van den Hoff J, Steinbach J, Krex D, Schmitz-Schackert G, Falk M, Baumann M, Krause M. (2020) Final results of the prospective biomarker trial PETra: [11C]-MET-accumulation in postoperative PET/MRI predicts outcome after radiochemotherapy in glioblastoma. Clin Cancer Res. 2020 Dec 29:clincanres.1775.2020. doi: 10.1158/1078-0432.CCR-20-1775.

Suckert T, Rassamegevanon T, Müller J, Dietrich A, Graja A, Reiche M, Löck S, Krause M, Beyreuther E, von Neubeck C. Applying Tissue Slice Culture in Cancer Research-Insights from Preclinical Proton Radiotherapy. Cancers (Basel). 2020; 12(6):E1589. doi: 10.3390/cancers12061589.

Raschke F, Seidlitz A, Wesemann T, Löck S, Jentsch C, Platzek I, Petr J, van den Hoff J, Kotzerke J, Beuthien-Baumann B, Baumann M, Linn J, Krause M, Troost EGC. Dose dependent cerebellar atrophy in glioma patients after radio(chemo)therapy. Radiother Oncol. 2020; 150:262-267. doi: 10.1016/j.radonc.2020.07.044.

Starke S, Leger S, Zwanenburg A, Leger K, Lohaus F, Linge A, Schreiber A, Kalinauskaite G, Tinhofer I, Guberina N, Guberina M, Balermpas P, von der Grün J, Ganswindt U, Belka C, Peeken JC, Combs SE, Boeke S, Zips D, Richter C, Troost EGC, Krause M, Baumann M, Löck S. 2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. Sci Rep. 2020; 10(1):15625. doi: 10.1038/s41598-020-70542-9.

Krause M, Alsner J, Linge A, Bütof R, Löck S, Bristow R. Specific requirements for translation of biological research into clinical radiation oncology. Mol Oncol. 2020; 14(7):1569-1576. doi: 10.1002/1878-0261.12671.

Zwanenburg A, Vallières M, Abdalah MA, Aerts HJ, et al. The Image Biomarker Standardization Initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328-338.

Bütof R, Löck S, Soliman M, Haase R, Perrin R, Richter C, Appold S, Krause M, Baumann M. Dose-volume predictors of early esophageal toxicity in non-small cell lung cancer patients treated with accelerated-hyperfractionated radiotherapy. Radiother Oncol. 2020 Feb;143:44-50. doi: 10.1016/j.radonc.2019.11.002. Epub 2019 Nov 22.

Vehlow A, Cordes N. DDR1 (discoidin domain receptor tyrosine kinase 1) drives glioblastoma therapy resistance by modulating autophagy. Autophagy. 2019 Aug;15(8):1487-1488. doi: 10.1080/15548627.2019.1618540. Epub 2019 May 23.